The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity

Physiological signalling by the epidermal growth factor receptor (EGFR) controls developmental processes and tissue homeostasis, whereas aberrant EGFR activity drives oncogenic cell transformation. Under normal conditions, the EGFR must therefore generate outputs of defined strength and duration. To this aim, cells balance EGFR activity via different modalities of negative signalling. Increasing attention is being drawn on transcriptionally controlled feedback inhibitors of EGFR, namely RALT/MIG6, LRIG1, SOCS4 and SOCS5. Genetic studies in mice have revealed the essential role of Ralt/Mig6 in regulating Egfr-driven skin morphogenesis and tumour formation, yet the mechanisms through which RALT abrogates EGFR activity are still undefined. We report that RALT suppresses EGFR function by inhibiting its catalytic activity. The evolutionarily conserved ErbB-binding region (EBR) is necessary and sufficient to carry out RALT-dependent suppression of EGFR kinase activityin vitro and in intact cells. The mechanism involves binding of the EBR to the 953RYLVIQ958 sequence, which is located in theαI helix of the EGFR kinase and has been shown to participate in allosteric control of EGFR catalytic activity. Our results uncover a novel mechanism of temporal regulation of EGFR activity in vertebrate organisms.

[1]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[2]  W. Alexander,et al.  Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Aaronson,et al.  EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. , 1990, Science.

[4]  G. Sala,et al.  Feedback inhibition by RALT controls signal output by the ErbB network , 2003, Oncogene.

[5]  Xiuli Wu,et al.  The Leucine-rich Repeat Protein LRIG1 Is a Negative Regulator of ErbB Family Receptor Tyrosine Kinases* , 2004, Journal of Biological Chemistry.

[6]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[7]  I. Amit,et al.  Suppressors of Cytokine Signaling 4 and 5 Regulate Epidermal Growth Factor Receptor Signaling* , 2005, Journal of Biological Chemistry.

[8]  G. Carpenter,et al.  Selective Cleavage of the Heregulin Receptor ErbB-4 by Protein Kinase C Activation* , 1996, The Journal of Biological Chemistry.

[9]  I. Amit,et al.  LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation , 2004, The EMBO journal.

[10]  D. Lauffenburger,et al.  Computational modeling of the EGF-receptor system: a paradigm for systems biology. , 2003, Trends in cell biology.

[11]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[12]  Salvatore Pece,et al.  Endocytosis and cancer. , 2004, Current opinion in cell biology.

[13]  Douglas Lauffenburger,et al.  Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. , 2003, Cancer research.

[14]  A. Schulze,et al.  Analysis of the transcriptional program induced by Raf in epithelial cells , 2001, Nature Genetics.

[15]  L. E. Johannessen,et al.  Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies , 2002, The Journal of cell biology.

[16]  L. Pelkmans,et al.  Not just a sink: endosomes in control of signal transduction. , 2004, Current opinion in cell biology.

[17]  M. Crescenzi,et al.  Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain , 2000, Molecular and Cellular Biology.

[18]  A. Zilberstein,et al.  Autophosphorylation of the intracellular domain of the epidermal growth factor receptor results in different effects on its tyrosine kinase activity with various peptide substrates. Phosphorylation of peptides representing Tyr(P) sites of phospholipase C-gamma. , 1991, The Journal of biological chemistry.

[19]  P. Transidico,et al.  Clathrin-independent endocytosis of ubiquitinated cargos. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Kyriakis,et al.  Gene 33 Is an Endogenous Inhibitor of Epidermal Growth Factor (EGF) Receptor Signaling and Mediates Dexamethasone-induced Suppression of EGF Function* , 2005, Journal of Biological Chemistry.

[21]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[22]  O. Smithies,et al.  TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. , 1993, Cell.

[23]  M. Sliwkowski,et al.  A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 Is Required for Transactivation of ErbB2* , 1999, The Journal of Biological Chemistry.

[24]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[25]  N. Copeland,et al.  The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. , 1994, Genes & development.

[26]  A. Citri,et al.  Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity* , 2005, Journal of Biological Chemistry.

[27]  Rüdiger Klein,et al.  Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation , 2006, Nature Medicine.

[28]  P. P. Di Fiore,et al.  Signaling through monoubiquitination. , 2004, Current topics in microbiology and immunology.

[29]  Chen Huiping,et al.  Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin , 2005, Oncogene.

[30]  O. Segatto,et al.  Negative regulation of receptor tyrosine kinase signals , 2001, FEBS letters.

[31]  R. Bronson,et al.  Evidence that MIG-6 is a tumor-suppressor gene , 2007, Oncogene.

[32]  David C. Lee,et al.  TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice , 1993, Cell.

[33]  J. Girard,et al.  Inhibition of Insulin Receptor Catalytic Activity by the Molecular Adapter Grb14* , 2002, The Journal of Biological Chemistry.

[34]  A. Lenferink,et al.  Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.

[35]  B. Shilo,et al.  Signaling by the Drosophila epidermal growth factor receptor pathway during development. , 2003, Experimental cell research.

[36]  Y. Yarden,et al.  Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes* , 1998, The Journal of Biological Chemistry.

[37]  A. Ullrich,et al.  Mig-6 Is a Negative Regulator of the Epidermal Growth Factor Receptor Signal , 2001, Biological chemistry.

[38]  Y. Yarden,et al.  Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases , 2004, Oncogene.

[39]  O. Segatto,et al.  Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved‐like phenotype , 2005, EMBO reports.

[40]  L. E. Johannessen,et al.  The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. , 2005, Molecular biology of the cell.

[41]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.